Dextrose Prolotherapy for Lower-Extremity Injuries: A Systematic Review

Abstract & Summary

01 · Introduction

Ehlers-Danlos Syndrome (EDS) is a connective tissue disorder characterized by joint hypermobility, skin hyperextensibility, and tissue elasticity. Scientists have classified thirteen subtypes of EDS; 80–90% of cases are the hypermobile subtype. Hypermobile EDS (hEDS) affects roughly 0.19% of the population, though under-recognition likely means the true prevalence is higher. Its primary feature is laxity of joint capsules, ligaments, and tendons. Unlike other EDS subtypes, there is no genetic test for hEDS, so diagnosis is clinical.

The 2017 International EDS Consortium criteria use three components: (1) the Beighton score (Figure 1) to assess generalized hypermobility — a 9-point checklist (positive at >6 for prepubertal children; ≥5 for pubertal children and adults; ≥4 for those over 50); (2) systemic manifestations, musculoskeletal complications, and/or family history; and (3) exclusion of other EDS subtypes, autoimmune disorders, and alternative diagnoses.

Figure 1. The Beighton criteria: (A) forward trunk flexion with knees extended, palms flat on the floor; (B&C) elbow hyperextension beyond 190°; (D&E) knee hyperextension beyond 190°; (F&G) thumb opposition to the forearm; (H&I) fifth-finger hyperextension beyond 90°.

hEDS patients live with the consequences of joint hypermobility: recurrent lower-extremity instability and subluxations at a young age, sprained ankles, buckling knees, and snapping hips — with real physical and psychological burden. Over time, these loose, unstable joints become arthritic, driving chronic pain. Traditional management combines approaches aimed at prevention rather than reversing tissue laxity: physiotherapy and core/joint-stabilization exercise (encouraging but under-studied), pain medications (short-term benefit only), and surgery (variable satisfaction, often worse than in non-hEDS patients). These limits point to a need for an approach that addresses the underlying tissue.

Dextrose prolotherapy is an inexpensive, minimally invasive option with promising musculoskeletal results. Hypertonic dextrose acts as an osmotic irritant that stimulates tissue growth when injected into injured muscle, tendon, ligament, and joint. Its mechanism isn’t fully understood, but it is thought to trigger a controlled local inflammation that releases growth factors and cytokines in the natural healing cascade, driving proliferation and strengthening of new connective tissue. Animal histology supports this: Kim and colleagues found a single injection of 5% or 20% dextrose into non-injured rat Achilles tendon significantly increased tendon diameter and fibroblast counts versus saline — suggesting a non-osmolar proliferative effect. We hypothesize that dextrose prolotherapy can help reverse the hEDS disease state by strengthening supporting joint tissue to reduce hypermobility and discomfort. Our aim is to summarize the latest lower-extremity prolotherapy research and draw correlations to hEDS.

02 · Methods

Objective. To systematically review dextrose prolotherapy for lower-extremity musculoskeletal injuries in both hypermobile and non-hypermobile patients.

Data sources & selection. PubMed, Healthline, OmniMedicalSearch, Medscape, and EMBASE were searched from 1990 to November 2021, following a protocol similar to the Hauser 2016 dextrose prolotherapy review. Keywords: prolotherapy, dextrose, regenerative injection therapy, musculoskeletal pain. Inclusion: human subjects, peer-reviewed, dextrose as the sole proliferant. Exclusion: upper-extremity injuries, and solutions containing P2G, pumice, PRP, bone marrow, lipoaspirate, stem cells, or sodium morrhuate. Non-English studies were included if they had an English abstract and sufficient tabular/graphic data.

Outcomes. Studies assessed pain intensity from baseline via the visual analog scale (VAS) or numerical rating scale (NRS). A 2-point NRS reduction is the minimal clinically important change (MCID); ≤1.5 points is clinically irrelevant. Osteoarthritis studies used the WOMAC (100-point) index. Study heterogeneity and limited RCTs prevented a meta-analysis.

03 · Results — Lower Back & SI Joint

Abnormal imaging shouldn’t be assumed to be the cause of low back pain; most cases without neurological findings are myofascial. Notably, lumbar-spine surgery complication rates in hEDS have been reported as high as 50%, so minimally invasive options matter for this population. In 1999, Dechow et al. (RCT) found no significant difference between a dextrose-glycerine-phenol solution and control at 6 months. In 2016, Maniquis-Smigel et al. (RCT) found 5% dextrose caudal epidural injections gave superior pain relief at 15 min–48 h but not at 2 weeks — suggesting a neurogenic effect at the dorsal-root level; given doubts about long-term epidural efficacy, it’s not advisable for chronic back pain. Several case series showed benefit. For the sacroiliac (SI) joint — commonly unstable in hEDS — Kim et al. (the first and only RCT) found intra-articular dextrose gave longer-lasting relief than steroid (58.7% vs 10.2% achieving ≥50% relief at 15 months). Three SI case series reported symptomatic relief.

Table 1 · Lower Back & SI Joint evidence

Summary. Level IV evidence supports dextrose prolotherapy for lumbar-origin low back pain (protocols should be tailored to pain etiology), and there is evidence for SI-joint-related pain — a common issue in hypermobile patients, making prolotherapy an attractive conservative option.

04 · Results — Hip & Groin

hEDS patients’ capsuloligamentous laxity drives hip instability, recurrent subluxations/dislocations, and, if undertreated, premature arthritis. The only hip RCT studied osteoarthritis from developmental hip dysplasia (which occurs in ~4% of EDS vs ~0.1% generally): Gül et al. found 15% dextrose outperformed exercise on VAS at 6 months and Harris Hip Score at 6 and 12 months. Two case series (Topol & Reeves) found meaningful improvement in athletic groin pain, with most athletes returning to unrestricted sport.

Table 2 · Hip & Groin evidence

Summary. Current evidence supports dextrose prolotherapy for hip and groin tendon pathology. Gül’s protocol could be adapted to the lax-tendon hEDS population; more trials (including hip OA) would broaden the scope.

05 · Results — Knee

Knee instability — patellar subluxation/dislocation — is common in hEDS and drives premature patellofemoral arthritis; nearly all hEDS patients report arthritis before 40. For patellar tendinopathy, Ryan et al. (pilot) found improved function and tendon integrity on ultrasound at 45 weeks. For knee OA, the evidence is strongest: Reeves & Hassanein (the first RCT) found dextrose improved pain, swelling, buckling, and range of motion, with radiographic stability; Rabago et al. (two Level 1 studies) found dextrose superior to saline/exercise on WOMAC at 52 weeks, with MRI evidence of cartilage growth; and two 2017 RCTs found peri- and intra-articular approaches both effective (one favoring peri-articular on VAS).

Table 3 · Knee evidence

Summary. There is solid evidence for dextrose prolotherapy in knee OA. Standardizing pre/post-treatment protocols is the next step. Because the hEDS knee lacks joint integrity plus has patellar pathology, we would recommend both intra- and peri-articular injection.

06 · Results — Foot & Ankle

Ankle instability is common in hEDS and contributes to falls and to knee/hip/back malalignment. For plantar fasciitis, several RCTs support dextrose: Ersen et al. found superior VAS/FAOS at one year vs stretching; Uğurlar et al. found dextrose and PRP effective at 3–12 months (no difference among treatments by 36 months); and trials against shockwave and corticosteroid showed comparable results by 12 weeks. For Achilles tendinopathy, Yelland et al. found combined dextrose + eccentric exercise superior for pain/stiffness/activity, and Chan et al. reported favorable case-series results. For ankle OA / osteochondral lesions, Akpancar & Gül found dextrose and PRP gave similar 1-year benefit, with dextrose cheaper and less invasive.

Table 4 · Foot & Ankle evidence

Summary. There is encouraging evidence for dextrose prolotherapy across foot and ankle pathology. Further work on injection protocols is needed, particularly in the hEDS population.

07 · Discussion

There is encouraging evidence for dextrose prolotherapy in lower-extremity injuries, with the most robust data — multiple Level I studies — in knee OA. Across the reviewed studies, dextrose was inexpensive, minimally invasive, and free of adverse effects beyond local injection inflammation. Yet most insurers don’t cover it, sharply limiting access. Because hEDS patients have few good options to begin with, our hope is that further research legitimizes prolotherapy for hEDS pathology and leads to insurance coverage.

To date, no RCT or case series has studied dextrose prolotherapy in a solely hEDS population — a blank slate for building a standardized protocol. The reviewed studies used varied dextrose concentrations, anesthetics, volumes, and injection techniques; standardization would improve consistency and acceptance. Research is lacking in hEDS overall, but the recent studies here reflect a real shift toward hypermobility research. Limitations of this review include publication bias and heterogeneity in protocols, intervals, and follow-up. (See our companion upper-extremity review for the analogous head-to-toe picture.)

Summary of the reviewed dextrose prolotherapy evidence by region.

This review is provided for education and professional reference and reflects the cited literature; it is not medical advice and does not create a physician–patient relationship. Dextrose prolotherapy protocols vary and are not universally insurance-covered. Study links resolve to the source (a few landmark studies link directly; others open a PubMed search for the exact paper). The Fascia Institute and Treatment Center® · 2520 Harvard Ave, Ste 2B, Metairie, LA 70001 · (504) 704-1254 · Follow the Tulane Hypermobility & EDS program on Facebook.